CXCR4 chemokine receptor signaling mediates pain hypersensitivity in association with antiretroviral toxic neuropathy

Sonia K. Bhangoo, Dongjun Ren, Richard J. Miller, David M. Chan, Matthew S. Ripsch, Clarissa Weiss, Christian McGinnis, Fletcher White

Research output: Contribution to journalArticle

114 Citations (Scopus)

Abstract

Nucleoside reverse transcriptase inhibitors (NRTIs) are known to produce painful neuropathies and to enhance states of pain hypersensitivity produced by HIV-1 infection. It has also been observed that in some neuropathic pain models, chemokines and their receptors are upregulated, perhaps contributing to the pain state. In order to understand if chemokines are involved in NRTI-mediated sensory neuropathies, we treated rats with the anti-retroviral drug, 2′,3′-dideoxycytidine (ddC), which is known to produce an extended period of hyperalgesia and allodynia. Using in situ hybridization, we observed that under normal conditions, CXCR4 chemokine receptors were widely expressed by satellite glia in the dorsal root ganglia (DRG) and Schwann cells in the sciatic nerve. A limited number of DRG neurons also expressed CXCR4 receptors. The chemokine SDF-1/CXCL12 was similarly expressed in glial cells in the DRG and peripheral nerve. Following a single administration of ddC, expression levels of CXCR4 mRNA in glia and neurons and SDF-1 mRNA in glia increased considerably. The functional nature of increased CXCR4 mRNA expression was confirmed by measuring SDF-1 induced [Ca2+]i increases in acutely isolated DRG neurons and glia. In contrast, the expression of the chemokine receptors CCR2 and CCR5 did not change following ddC treatment. Pain hypersensitivity produced by ddC could be inhibited by treatment with the CXCR4 antagonist, AMD3100. Hence, we postulate that NRTIs produce pain hypersensitivity through the upregulation of CXCR4 signaling in the DRG. Increased numbers of CXCR4 receptors would also explain the synergism observed between NRTI treatment and the proalgesic effects of HIV-1 infection.

Original languageEnglish (US)
Pages (from-to)581-591
Number of pages11
JournalBrain, Behavior, and Immunity
Volume21
Issue number5
DOIs
StatePublished - Jul 2007
Externally publishedYes

Fingerprint

CXCR4 Receptors
Zalcitabine
Chemokine Receptors
Poisons
Spinal Ganglia
Neuroglia
Reverse Transcriptase Inhibitors
Hypersensitivity
Nucleosides
Pain
Hyperalgesia
Chemokines
Neurons
Messenger RNA
HIV Infections
HIV-1
Schwann Cells
Neuralgia
Sciatic Nerve
Peripheral Nerves

Keywords

  • Chemokine
  • CXCR4
  • HAART
  • HIV
  • Neuropathic pain
  • SDF1

ASJC Scopus subject areas

  • Immunology
  • Behavioral Neuroscience
  • Endocrine and Autonomic Systems

Cite this

CXCR4 chemokine receptor signaling mediates pain hypersensitivity in association with antiretroviral toxic neuropathy. / Bhangoo, Sonia K.; Ren, Dongjun; Miller, Richard J.; Chan, David M.; Ripsch, Matthew S.; Weiss, Clarissa; McGinnis, Christian; White, Fletcher.

In: Brain, Behavior, and Immunity, Vol. 21, No. 5, 07.2007, p. 581-591.

Research output: Contribution to journalArticle

Bhangoo, Sonia K. ; Ren, Dongjun ; Miller, Richard J. ; Chan, David M. ; Ripsch, Matthew S. ; Weiss, Clarissa ; McGinnis, Christian ; White, Fletcher. / CXCR4 chemokine receptor signaling mediates pain hypersensitivity in association with antiretroviral toxic neuropathy. In: Brain, Behavior, and Immunity. 2007 ; Vol. 21, No. 5. pp. 581-591.
@article{229b4ea63ea24b2b93d18572a33d5669,
title = "CXCR4 chemokine receptor signaling mediates pain hypersensitivity in association with antiretroviral toxic neuropathy",
abstract = "Nucleoside reverse transcriptase inhibitors (NRTIs) are known to produce painful neuropathies and to enhance states of pain hypersensitivity produced by HIV-1 infection. It has also been observed that in some neuropathic pain models, chemokines and their receptors are upregulated, perhaps contributing to the pain state. In order to understand if chemokines are involved in NRTI-mediated sensory neuropathies, we treated rats with the anti-retroviral drug, 2′,3′-dideoxycytidine (ddC), which is known to produce an extended period of hyperalgesia and allodynia. Using in situ hybridization, we observed that under normal conditions, CXCR4 chemokine receptors were widely expressed by satellite glia in the dorsal root ganglia (DRG) and Schwann cells in the sciatic nerve. A limited number of DRG neurons also expressed CXCR4 receptors. The chemokine SDF-1/CXCL12 was similarly expressed in glial cells in the DRG and peripheral nerve. Following a single administration of ddC, expression levels of CXCR4 mRNA in glia and neurons and SDF-1 mRNA in glia increased considerably. The functional nature of increased CXCR4 mRNA expression was confirmed by measuring SDF-1 induced [Ca2+]i increases in acutely isolated DRG neurons and glia. In contrast, the expression of the chemokine receptors CCR2 and CCR5 did not change following ddC treatment. Pain hypersensitivity produced by ddC could be inhibited by treatment with the CXCR4 antagonist, AMD3100. Hence, we postulate that NRTIs produce pain hypersensitivity through the upregulation of CXCR4 signaling in the DRG. Increased numbers of CXCR4 receptors would also explain the synergism observed between NRTI treatment and the proalgesic effects of HIV-1 infection.",
keywords = "Chemokine, CXCR4, HAART, HIV, Neuropathic pain, SDF1",
author = "Bhangoo, {Sonia K.} and Dongjun Ren and Miller, {Richard J.} and Chan, {David M.} and Ripsch, {Matthew S.} and Clarissa Weiss and Christian McGinnis and Fletcher White",
year = "2007",
month = "7",
doi = "10.1016/j.bbi.2006.12.003",
language = "English (US)",
volume = "21",
pages = "581--591",
journal = "Brain, Behavior, and Immunity",
issn = "0889-1591",
publisher = "Academic Press Inc.",
number = "5",

}

TY - JOUR

T1 - CXCR4 chemokine receptor signaling mediates pain hypersensitivity in association with antiretroviral toxic neuropathy

AU - Bhangoo, Sonia K.

AU - Ren, Dongjun

AU - Miller, Richard J.

AU - Chan, David M.

AU - Ripsch, Matthew S.

AU - Weiss, Clarissa

AU - McGinnis, Christian

AU - White, Fletcher

PY - 2007/7

Y1 - 2007/7

N2 - Nucleoside reverse transcriptase inhibitors (NRTIs) are known to produce painful neuropathies and to enhance states of pain hypersensitivity produced by HIV-1 infection. It has also been observed that in some neuropathic pain models, chemokines and their receptors are upregulated, perhaps contributing to the pain state. In order to understand if chemokines are involved in NRTI-mediated sensory neuropathies, we treated rats with the anti-retroviral drug, 2′,3′-dideoxycytidine (ddC), which is known to produce an extended period of hyperalgesia and allodynia. Using in situ hybridization, we observed that under normal conditions, CXCR4 chemokine receptors were widely expressed by satellite glia in the dorsal root ganglia (DRG) and Schwann cells in the sciatic nerve. A limited number of DRG neurons also expressed CXCR4 receptors. The chemokine SDF-1/CXCL12 was similarly expressed in glial cells in the DRG and peripheral nerve. Following a single administration of ddC, expression levels of CXCR4 mRNA in glia and neurons and SDF-1 mRNA in glia increased considerably. The functional nature of increased CXCR4 mRNA expression was confirmed by measuring SDF-1 induced [Ca2+]i increases in acutely isolated DRG neurons and glia. In contrast, the expression of the chemokine receptors CCR2 and CCR5 did not change following ddC treatment. Pain hypersensitivity produced by ddC could be inhibited by treatment with the CXCR4 antagonist, AMD3100. Hence, we postulate that NRTIs produce pain hypersensitivity through the upregulation of CXCR4 signaling in the DRG. Increased numbers of CXCR4 receptors would also explain the synergism observed between NRTI treatment and the proalgesic effects of HIV-1 infection.

AB - Nucleoside reverse transcriptase inhibitors (NRTIs) are known to produce painful neuropathies and to enhance states of pain hypersensitivity produced by HIV-1 infection. It has also been observed that in some neuropathic pain models, chemokines and their receptors are upregulated, perhaps contributing to the pain state. In order to understand if chemokines are involved in NRTI-mediated sensory neuropathies, we treated rats with the anti-retroviral drug, 2′,3′-dideoxycytidine (ddC), which is known to produce an extended period of hyperalgesia and allodynia. Using in situ hybridization, we observed that under normal conditions, CXCR4 chemokine receptors were widely expressed by satellite glia in the dorsal root ganglia (DRG) and Schwann cells in the sciatic nerve. A limited number of DRG neurons also expressed CXCR4 receptors. The chemokine SDF-1/CXCL12 was similarly expressed in glial cells in the DRG and peripheral nerve. Following a single administration of ddC, expression levels of CXCR4 mRNA in glia and neurons and SDF-1 mRNA in glia increased considerably. The functional nature of increased CXCR4 mRNA expression was confirmed by measuring SDF-1 induced [Ca2+]i increases in acutely isolated DRG neurons and glia. In contrast, the expression of the chemokine receptors CCR2 and CCR5 did not change following ddC treatment. Pain hypersensitivity produced by ddC could be inhibited by treatment with the CXCR4 antagonist, AMD3100. Hence, we postulate that NRTIs produce pain hypersensitivity through the upregulation of CXCR4 signaling in the DRG. Increased numbers of CXCR4 receptors would also explain the synergism observed between NRTI treatment and the proalgesic effects of HIV-1 infection.

KW - Chemokine

KW - CXCR4

KW - HAART

KW - HIV

KW - Neuropathic pain

KW - SDF1

UR - http://www.scopus.com/inward/record.url?scp=34249737450&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249737450&partnerID=8YFLogxK

U2 - 10.1016/j.bbi.2006.12.003

DO - 10.1016/j.bbi.2006.12.003

M3 - Article

C2 - 17292584

AN - SCOPUS:34249737450

VL - 21

SP - 581

EP - 591

JO - Brain, Behavior, and Immunity

JF - Brain, Behavior, and Immunity

SN - 0889-1591

IS - 5

ER -